Drugs / GIM-407
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06536101 | Sep 2024 → Apr 2025 | — | Georgiamune Inc | Completed | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2024-09-24 | Georgiamune Inc | Georgiamune Announces First Participant Dosed in First-In-Class Phase 1 Healthy Volunteers Trial of GIM-407 georgiamune.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GIM-407 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06536101 ↗ |
| Route | Oral | “planned to be orally dosed” NCT06536101 ↗ |